毕得医药：公司董事长、总经理戴岚计划减持不超过总股本0.16%的公司股份

Core Viewpoint - Bid Pharma announced that its controlling shareholder, Ms. Dai Lan, plans to reduce her shareholding in the company due to personal financial needs, with a maximum reduction of 148,835 shares, representing 0.16% of the total share capital [1] Group 1 - The reduction plan will commence 15 trading days after the announcement and will be executed within a three-month period [1] - The shares will be sold through centralized bidding on the market [1] - The selling price will be determined based on the market price at the time of the actual reduction [1]